Last update 01 Jul 2024

Alprazolam

Last update 01 Jul 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care.

Drug Type

Small molecule drug

Synonyms

8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem, AP-1002

+ [16]

Target

DOCK5 x GABAA receptor

Mechanism

DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

AnxietyCatatoniaDepressive Disorder+ [5]

Inactive Indication

Drug abuseMild asthmaPanic

Originator Organization

Takeda Pharmaceutical Co., Ltd.Upjohn Pharmaceuticals Ltd.

Active Organization

UCB SAUpjohn US 2 LLC

UCB Trading (Shanghai) Co., Ltd.

+ [6]

Inactive Organization

Engage Therapeutics, Inc.Startup

UCB, Inc.

UCB Pharma GmbH

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (16 Oct 1981),

Anxiety DisordersPanic Disorder

RegulationBreakthrough Therapy (CN)

Structure

Molecular FormulaC17H13ClN4

InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N

CAS Registry28981-97-7

113

Clinical Trials associated with Alprazolam

NCT06293638 / RecruitingNot Applicable

Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor

The purpose of this study is to collect electrophysiological data related to functional brain network changes in patients undergoing deep brain stimulation for the treatment of essential tremor. Participants will be asked to remain seated with their head inside of a Magnetoencephalography (MEG) recording system as resting-state and task-related data are acquired. Spontaneous electrophysiological activity will be recorded in both the eyes open and eyes closed conditions with the participant seated comfortably. These recordings will be repeated in the DBS OFF and DBS ON states, with the ON state involving specific settings identified as optimal, sub-optimal, or ineffective at achieving tremor control. They will also be repeated following the optional administration non-DBS tremor mitigation techniques, which may include one or more of 1) cooling the limb, 2) oral administration of alprazolam, 3) oral consumption of ethanol (alcohol), or 4) peripheral nerve stimulation.

Start Date25 Mar 2024

Sponsor / Collaborator

The Cleveland Clinic Foundation

NCT05006079 / RecruitingPhase 2IIT

Opioid/Benzodiazepine Polydrug Abuse: Integrating Research on Mechanisms, Treatment and Policies - Study 3

In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control.

Start Date13 Mar 2024

Sponsor / Collaborator

Wayne State University (Michigan)

[+1]

NCT06357104 / CompletedPhase 4IIT

Detoxification From the Lipid Tract by Cocktail Design

Apart from electroencephalogram biofeedback and electrical brain stimulation adopted for maintenance treatment, the study utilizes ultra-low frequency transcranial magnetic stimulation (ULF-TMS) for initial γ-aminobutyric acid (GABA) stimulation. The cocktail therapy starts after the primary efficacy endpoint, and concomitant therapy is adopted throughout the study.

Start Date26 Feb 2024

Sponsor / Collaborator

First Affiliated Hospital of Chongqing Medical University

100 Clinical Results associated with Alprazolam

100 Translational Medicine associated with Alprazolam

100 Patents (Medical) associated with Alprazolam

2,591

Literatures (Medical) associated with Alprazolam

01 Mar 2024·Value in health regional issues

Evolving Trends and Economic Burden of Benzodiazepine Use: Insights From a 10-Year Predictive Model

Article

Author: Marcec, Robert ; Koren, Luciana ; Likic, Robert ; Koren, Andro ; Marcinko, Darko

OBJECTIVES:

Benzodiazepines (BZDs) are widely prescribed in Croatia to treat anxiety, insomnia, mood disorders, and epileptic seizures. Long-term BZD use is associated with memory loss, Alzheimer's disease, dependence, addiction, falls in elderly populations, and increased traffic accident risk.

METHODS:

Drug consumption data were obtained from the Agency for Medicinal Products and Medical Devices of Croatia website. Autoregressive integrated moving average models, constructed using R programming language, forecasted diazepam, alprazolam, and overall BZD utilization and financial costs at a national level over 10 years.

RESULTS:

BZD consumption increased by up to 18.6% between 2012 and 2020. During the same period, diazepam utilization rose by 29.1%, and alprazolam consumption increased by 19.4%. Our model predicts that, by 2032, BZD, diazepam, and alprazolam utilization will increase substantially. The total projected financial expenditure for BZDs in 2032 is estimated at 14.22 million euros, with diazepam and alprazolam expenditures at 7.39 and 4.12 million euros, respectively. These increases will result in significant growth in healthcare spending and a rise in adverse effects related to long-term use.

CONCLUSIONS:

National healthcare decision makers should consider implementing regulatory and legislative measures to quantify, specify, and limit monthly BZD use for each patient. This would help control the negative side effects of prolonged BZD use while continuing to provide treatment for patients who genuinely need it.

01 Feb 2024·Pharmacology, biochemistry, and behavior

Discriminative stimulus and reinforcing effects of diclazepam in rodents

Article

Author: Lee, Wonjong ; Lee, Jung Won ; Kim, Jin Mook ; Youn, Dong-Hyun ; Kim, Sungsun ; Park, Seong Hye ; Kwon, Chan Hyeok ; Choi, Sun-Ok

Diclazepam, a designer benzodiazepine, is a lesser-known novel anxiolytic substance and a structural analog of diazepam. Although several case studies have reported the adverse effects of diclazepam, their potential impacts remain unknown. Therefore, this study aimed to determine the effects of diclazepam in rodents using drug discrimination, locomotor activity, self-administration (SA), and conditioned place preference (CPP) tests. Sprague-Dawley rats (male, 8 weeks old, weighing 220-450 g, n = 12 per group) and C57BL/6 mice (male, 7 weeks old, weighing 20-25 g, n = 7-8 per group) were administered alprazolam, morphine, and diclazepam. Diclazepam fully elicited alprazolam-appropriate dose-dependent lever responses (>80 %) similar to those of alprazolam. In rats administered 0.5 mg/kg of morphine, a partial substitution (80 %-20 %) was observed. Mice receiving intraperitoneal injections of diclazepam (0.05, 0.2, and 2 mg/kg) showed decreased locomotor activity. In the SA experiment, mice that self-administered intravenous diclazepam (2 μg/kg/infusion) showed significantly higher infusion and active lever responses compared to the vehicle group. No statistically significant rewarding effects of diclazepam at the doses of 0.2 and 2 mg/kg evaluated using the CPP paradigm were found. In conclusion, diclazepam has reinforcing effects and shares the interoceptive effects of alprazolam. Therefore, legal restrictions on the use of diclazepam should be carefully considered.

09 Jan 2024·Parkinson's disease

Alprazolam Reduces Freezing of Gait (FOG) and Improves FOG-Related Gait Deficiencies

Article

Author: Al Jaja, Abdullah ; MacDonald, Penny A ; Seergobin, Ken N ; Grahn, Jessica A ; Sue, Téa ; Prenger, Margaret

Background. Freezing of gait (FOG) is an intractable motor symptom in Parkinson’s disease (PD) that increases fall risk and impairs the quality of life. FOG has been associated with anxiety, with experimental support for the notion that anxiety itself provokes FOG. We investigated the effect of acute anxiety reduction via alprazolam on FOG in PD. Methods. In ten patients with PD, FOG, and normal cognition, we administered 0.25 mg alprazolam in one session and placebo in another, in counterbalanced order. At each session, on separate days, patients walked on a pressure-sensitive walkway. Using Oculus Rift virtual-reality goggles, patients walked along a plank that appeared to be (a) level with the floor, in the low-anxiety condition or (b) raised high above the ground, in the high-anxiety conditions. In this way, we assessed the impacts of anxiety and alprazolam (i.e., anxiety reduction) on FOG frequency and other gait parameters. Results. FOG events appeared only in the high-anxiety conditions. Alprazolam significantly reduced subjective and objective measures of anxiety, as well as the prevalence of FOG (

p = 0.05

). Furthermore, alprazolam improved swing time (

p < 0.05

) and gait variability in all conditions, particularly during the elevated plank trials. Interpretation. Our results suggest that (1) anxiety induces FOG, and (2) alprazolam concomitantly reduces anxiety and FOG. Alprazolam further improved gait stability (i.e., swing time and gait variability). These findings reveal that anxiety triggers FOG in PD. Treating anxiety can reduce FOG and improve gait stability, potentially offering new therapeutic avenues for this intractable and disabling symptom in PD.

News (Medical) associated with Alprazolam

24 Jun 2024

·www.globenewswire.com

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, is pleased to announce that AKYNZEO® (fosnetupitant/palonosetron) injection is now available in the US in a ready-to-use vial. AKYNZEO injection (Ready-to-Use) is a new method of administration and contains the same formulation as the prior AKYNZEO Injection (To-be-Diluted). The features of the new ready-to-use presentation of AKYNZEO injection include: No reconstitution or dilution required; infuse directly from the vial using a built-in hanging strapNo refrigeration required at any point during distribution, storage, or preparationAccessible via automated dispensing machine, allowing the product to be stored and available near the location of patient care AKYNZEO injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. It has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO injection does not contain polysorbate 80 or allergenic excipients such as soy or egg lecithin. It can be administered simultaneously with intravenous dexamethasone sodium phosphate. Dr. Melanie Rolli, Helsinn Group CEO, commented: “As a pioneer in cancer supportive care, Helsinn continues to be unwavering in our pursuit to help patients and clinicians in cancer care. We are very pleased to launch the new AKYNZEO Ready-to-Use vial, building on our legacy of innovation.” Ordering information Clinicians wishing to order the new vial should contact their GPO or distributor. The National Drug Code (NDC) number for AKYNZEO injection vial with hanger (Ready-to-Use) is 69639-106-01 and the J Code is J1454 (Injection, fosnetupitant 235 mg and palonosetron 0.25 mg); billing unit (single dose vial [SDV]). About AKYNZEO® AKYNZEO is the first and only 5-HT3 and NK1 receptor antagonists fixed combination approved for the prevention of chemotherapy-induced acute and delayed nausea and vomiting. A single dose of AKYNZEO given with dexamethasone has been shown to prevent chemotherapy-induced nausea and vomiting for up to 5 days. INDICATION AKYNZEO (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Limitations of Use AKYNZEO injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. AKYNZEO is a combination of palonosetron, a serotonin-3 (5-HT3) receptor antagonist, and fosnetupitant, a substance P/neurokinin-1 (NK-1) receptor antagonist: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. IMPORTANT SAFETY INFORMATION Warnings and Precautions Hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving palonosetron, one of the components of AKYNZEO, with or without known hypersensitivity to other 5-HT3 receptor antagonists.Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue AKYNZEO and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if AKYNZEO is used concomitantly with other serotonergic drugs. Adverse Reactions Most common adverse reactions (≥3%) for AKYNZEO capsules are headache, asthenia, dyspepsia, fatigue, constipation and erythema. The safety profile of AKYNZEO injection was generally similar to AKYNZEO capsules. Drug Interactions Use with caution in patients receiving concomitant medications primarily metabolized by CYP3A4. The plasma concentrations of CYP3A4 substrates can increase when co-administered with AKYNZEO. The inhibitory effect on CYP3A4 can last for multiple days Dexamethasone doses should be reduced when given with AKYNZEO. A more than two- fold increase in the systemic exposure of dexamethasone was observed 4 days after a single infusion of fosnetupitant.Consider the potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) when administering with AKYNZEO. When administered with netupitant, the systemic exposure to midazolam was significantly increased. Avoid concomitant use of AKYNZEO in patients on chronic use of a strong CYP3A4 inducer such as rifampin as this may decrease the efficacy of AKYNZEO. Use in Specific Populations Avoid use of AKYNZEO in patients with severe hepatic impairment, severe renal impairment, or end-stage renal disease.Advise women of potential risk to fetus; limited data are available; may cause fetal harm. For more information about AKYNZEO® please see the full US Prescribing Information. About Helsinn Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland, has direct commercial operations in the U.S. and an extensive network of long-standing trusted partners enabling a commercial presence in more than 90 countries. Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. Helsinn is proud of its history of operating with great integrity, passion and quality. The company is committed to continuously striving for innovation for its patients and embracing sustainable growth as a core element of its strategic vision. To learn more about Helsinn, please visit www.helsinn.com or follow us on LinkedIn and X. For more information: Helsinn Group Media Contact:Sabrina PerucchiGroup Communication ManagerLugano, Switzerland Tel: +41 (0) 91 985 21 21 Email: Info-hhc@helsinn.com

Drug ApprovalClinical Result

20 Jun 2024

·www.biospace.com

Luxor Scientific Unveils Cutting-Edge Testing Solutions to Combat Escalating Illicit Drug Crisis

Greenville, SC June 20, 2024 – Luxor Scientific, a leader in scientific research, announces groundbreaking advancements in combatting the rise of deadly illicit drugs. Leveraging expertise in toxicology, Luxor has developed advanced testing solutions to address the nation’s overdose crises associated with substances like bromazolam, tianeptine, xylazine, and nitazenes, providing healthcare professionals the information needed to develop more effective treatment plans. Bromazolam, often labeled as 'Fake Xanax,' is misrepresented as genuine Xanax, leading to a surge in overdose incidents and widespread concern among healthcare and law enforcement. Consumed orally to alleviate anxiety and panic, bromazolam's availability online exacerbates the risk. Similarly, tianeptine, known as 'gas station heroin,' administered intravenously for a euphoric effect, has recently prompted Louisiana to ban it due to reports of seizures and loss of consciousness. Additionally, the emergence of xylazine, a potent horse tranquilizer mixed with fentanyl, exacerbates the crisis, causing zombie-like behavior in users. Luxor Scientific's innovative testing solutions mark a significant advancement in combating illicit drug proliferation, providing precise detection of hazardous substances in easily collected body fluids. Our commitment to updating our test menu ensures we stay ahead in addressing evolving drug trends. Using state-of-the-art technology and extensive toxicology experience, our testing protocols empower stakeholders to respond effectively, safeguarding public health. Detection of novel illicit drugs is exclusive to experienced labs like Luxor Scientific. Luxor’s ability to detect illicit drug use in urine and oral fluid, along with rapid turnaround times, ensures life-saving results within 24 to 48 hours, critical for immediate intervention in emergency situations. “As a leading force in scientific research and innovation, Luxor Scientific is committed to leveraging our expertise to address pressing societal challenges such as the proliferation of illicit drugs,” stated Dr. Marion Snyder, Chief Science Officer at Luxor Scientific. “Our cutting-edge testing solutions represent a significant milestone in our ongoing efforts to combat the devastating impact of substance use disorder, empowering communities with the tools needed to safeguard public health and effectively treat patients.” Luxor Scientific has the capability to detect over 100 drugs and metabolites, including novel illicits. With an unwavering mission towards scientific excellence and social responsibility, Luxor Scientific is dedicated to effecting positive change in the face of adversity. As communities grapple with the escalating threat posed by novel illicit drugs, Luxor Scientific stands ready to partner with stakeholders across sectors to confront this crisis head-on and build a safer, healthier future for all. Healthcare providers concerned they are not identifying all the illicit substances their patients could be consuming or co-addicted can email Luxor Scientific at clientservices@luxorscientific.org or call 864-568-8940. About Luxor Scientific Luxor Scientific was founded with the mission of providing better information faster. As a full-service privately-held CAP-accredited medical and research laboratory, Luxor offers a robust menu of clinical and anatomical testing services. Today, Luxor Scientific is one of the fastest-growing companies in the southeast, specializing in cutting-edge diagnostic testing solutions in the areas of metabolomics, genomics, toxicology and histology. Luxor’s industry-leading turnaround times and state-of-the-art equipment and diagnostic solutions, allows Luxor to provide personalized service, accurate testing, and innovative functional reporting. For more information about Luxor Scientific and our full test offering, please visit . Media Contact: Kristina Loughrey kristina@klcoms.com 864.360.5848

Diagnostic Reagents

13 Jun 2024

·www.sciencedaily.com

Neural balance in the brain is associated with brain maturity and better cognitive ability

The E/I ratio of children decreases with healthy development. Children with a lower E/I ratio were observed to have better performance than their peers in cognitive tests such as memory and intelligence, according to researchers. In a world where external and internal stimuli can throw our entire body system off balance, how does our brain prevent itself from becoming overly stimulated? The answer lies in our brain's ability to maintain the balance of neural excitation (E) and inhibition (I), known as the E/I ratio. By regulating the E/I ratio, the brain prevents over-stimulation and under-stimulation. The E/I ratio of children decreases with healthy development. Children with a lower E/I ratio were observed to have better performance than their peers in cognitive tests such as memory and intelligence, according to studies by researchers from the Centre for Sleep and Cognition at the Yong Loo Lin School of Medicine (NUS Medicine). With the aim of drawing meaningful connections between E/I ratio and brain maturation, the study team, led by fourth-year PhD student Zhang Shaoshi, Associate Professor Thomas Yeo from the Centre for Sleep and Cognition at NUS Medicine, Assistant Professor Bart Larsen from the University of Minnesota and Associate Professor Theodore Satterthwaite from the University of Pennsylvania, looked at how E/I ratio changes in youths, by studying the MRI brain scans of 885 children, adolescents and young adults from the United States of America and 154 children from Singapore. E/I ratio is an aspect that is continually changing and developing throughout childhood and adolescence. The Singaporean data cohort were obtained from GUSTO, Singapore's largest and most comprehensive birth cohort study that seeks to help the next generation become healthier. Described as the Yin and Yang of the brain, researchers have found that too much excitation or excessive inhibition can be harmful, leading to a higher risk of developing brain disorders, such as autism, Alzheimer's disease and schizophrenia. In less severe situations, someone with too much excitation might overthink in social situations, resulting in anxiety. Indeed, a common drug for reducing anxiety symptoms is Xanax, which increases neural inhibition, thus reducing neural excitation. In more severe scenarios, over-excitation can cause an epileptic seizure. On the opposite end of the spectrum, too much inhibition indicates an absence of brain activity, effectively putting the person in a vegetative state. Therefore, inhibition is needed to balance excitation. Overall, a balanced E/I ratio is important for a well-functioning brain. Despite E/I's importance for brain health, it is hard to measure its ratio in the human brain without using invasive techniques. Therefore, the team developed a technique, combining artificial intelligence and biophysical modeling to infer E/I ratios from non-invasive, non-radioactive MRI scans. The team demonstrated the validity of their estimated E/I ratios through an experiment, during which participants ingested anti-anxiety medication (Xanax) or a placebo. The team's hypothesis is that once Xanax is ingested, inhibition will increase, so the overall E/I ratio decreases. To test this hypothesis, the research team scanned healthy individuals on two separate occasions. A participant is given Xanax before one MRI session and placebo in another MRI session. For some participants, Xanax might be administered in the first session, while for others Xanax might be administered in the second session. All parties involved in this experiment were not privy to whether an MRI session involved the placebo or the anti-anxiety drug. The team found that estimated E/I ratio markers were indeed lower after participants had ingested Xanax, compared with the placebo, and thus validating their technique. The study team then proceeded to use MRI brain scans to study brain development in a large sample of more than 1000 children, adolescents and young adults from Singapore and the United States of America. They discover that E/I ratios decrease with healthy development. Next, to establish the link between E/I ratios and cognitive function, the team divided participants, ranging from age 7 to 23, into high and low-performance groups based on their scores on certain cognitive tests. They found that the high performing groups had lower E/I ratios than their peers of the same age, suggesting that cognitive abilities improve as the E/I ratio matures during development. Beyond their study on neurodevelopment, the team is keen on applying their approach to gain mechanistic insights into various brain disorders, by studying how the E/I ratio differs between healthy participants and patients battling mental disorders. The team also aims to study how the E/I ratio changes as people age, to gain insights into neurodegenerative disorders, such as Alzheimer's Disease. Assoc Prof Thomas Yeo, who is also from the NUS College of Design and Engineering and Principal Investigator of this study, adds, "Our findings enhance our understanding of brain development and highlight potential avenues for understanding the emergence of psychopathology in youth. Hopefully, these findings will lead us to figure out which brain circuits get over-excited or over-inhibited easily, or pinpoint certain abnormal brain regions specific to an individual patient. This could shed more light on how medication or brain stimulation can be customised according to individuals, that would shape the course of treatment of brain disorders in the long run." This study is published in Proceedings of the National Academy of Sciences of the United States of America, titled 'In vivo whole-cortex marker of excitation-inhibition ratio indexes cortical maturation and cognitive ability in youth'.

100 Deals associated with Alprazolam

External Link

KEGG	Wiki	ATC	Drug Bank
D00225	Alprazolam	N05BA12	DB00404

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anxiety	JP	Teva Takeda Pharma Ltd.Startup	15 Feb 1984
Anxiety	JP	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Catatonia	JP	Teva Takeda Pharma Ltd.Startup	15 Feb 1984
Depressive Disorder	JP	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Depressive Disorder	JP	Teva Takeda Pharma Ltd.Startup	15 Feb 1984
Sleep Initiation and Maintenance Disorders	JP	Teva Takeda Pharma Ltd.Startup	15 Feb 1984
Sleep Initiation and Maintenance Disorders	JP	VIATRIS Pharmaceuticals Ltd.	15 Feb 1984
Anxiety Disorders	US	Upjohn US 2 LLC	16 Oct 1981
Anxiety Disorders	US	Viatris, Inc.	16 Oct 1981
Panic Disorder	US	Upjohn US 2 LLC	16 Oct 1981
Panic Disorder	US	Viatris, Inc.	16 Oct 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Status Epilepticus	Phase 3	US	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	CN	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	JP	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	AU	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	BG	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	CZ	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	FR	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	DE	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	HU	UCB Biopharma SRL	07 Dec 2021
Status Epilepticus	Phase 3	IT	UCB Biopharma SRL	07 Dec 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04970342 (CTgov)	Phase 1	-	13	Placebo (Lactose) Capsule+Cannabis (0%/ THC / 0% CBD) ("Sober" or Double Placebo)	lzgkzjdpmd(kampxxugve) = kqcpwswnyj ywzvihlheg (iowlluyxvx, bpxlufhqgi - oirznmcppd) View more	-	25 Jul 2023
				Cannabis (0%/ THC / 0% CBD)+0.75 mg Alprazolam Capsule (Active Alprazolam (Xanax), Placebo Cannabis)	lzgkzjdpmd(kampxxugve) = rwxntvtlnv ywzvihlheg (iowlluyxvx, doibtehicl - tmlsrvmyud) View more
NCT03478982 (ENGAGE-E-001, Pubmed)	Phase 2	Epilepsy	116	Staccato® alprazolam 1.0 mg	yqiyzridgg(klibiltlar) = ucgfksfkbs oslzmkvbjy (ffezutomho )	-	21 Oct 2022
				Staccato® alprazolam 2.0 mg	yqiyzridgg(klibiltlar) = fjsglydcwq oslzmkvbjy (ffezutomho )
NCT03478982 (P1.5-023, AAN2019)	Phase 2	Epilepsy	8	Staccato Alprazolam 1 mg	dgcycpxnzb(ljintlnfmq) = no adverse events were serious or severe kzdrdipmcs (glildqogqc )	Positive	09 Apr 2019
NCT03447353 (CTgov)	Phase 4	-	18	Placebo Oral Tablet ("Sober" or Double Placebo)	hdbaljokiv(reeeognckh) = jabiyljrsc khdhrqtrss (rpqkzlrzbt, oyvqwrgory - cuioigpisx) View more	-	27 Sep 2018
				Norco 10Mg-325Mg Tablet+Xanax 1Mg Tablet (Active Xanax, Active Norco)	hdbaljokiv(reeeognckh) = kvsqtokuxu khdhrqtrss (rpqkzlrzbt, pmuggkaahe - kclxdmklal) View more
NCT00477451 (CTgov)	Phase 2	Panic \| Panic Disorder	49	Inhaled placebo+IV doxapram (RCT Placebo)	bvcggkcivx(biljwadmvb) = zppodadlcf nfkbyrknzr (pkeypcpwuh, ntydrswjlm - icrvgpjpgz) View more	-	16 Jun 2017
				IV doxapram+Inhaled alprazolam 1 mg (RCT Alprazolam 1 mg)	bvcggkcivx(biljwadmvb) = fydrrmxceg nfkbyrknzr (pkeypcpwuh, pjlggtlfcz - kwlxlqpgim) View more
NCT01577706 (CTgov)	Not Applicable	Substance Abuse	7	Placebo (Placebo)	amrqtnhwsq(mbmtsbksve) = ngaadyiegd yidlatvbvq (bebqlhijmo, gduwfvkyhb - tnsvbmupho) View more	-	04 Apr 2017
				Alprazolam (Alprazolam)	amrqtnhwsq(mbmtsbksve) = gbelykzwka yidlatvbvq (bebqlhijmo, xnhaahzjui - icpodtxngv) View more
NCT00603980 (Pubmed \| Psychopharmacology (Berl))	Phase 1	Drug abuse	14	Inhaled alprazolam	kukirjbeiu(qtnrjcexnv) = donijclqgo oylecjskek (xhmmzwmrcz )	-	01 Mar 2015
				Oral alprazolam	kukirjbeiu(qtnrjcexnv) = zetyzimxuw oylecjskek (xhmmzwmrcz )
NCT01949038 (Pubmed \| Endoscopy)	Phase 2/3	-	220	Sublingual alprazolam	vctbuncfyu(tfgywjzwup) = vhbaoniqos jzufanvywh (dnoxqmgbfl )	Positive	01 Aug 2014
				Oral alprazolam	vctbuncfyu(tfgywjzwup) = kfhrqcbskl jzufanvywh (dnoxqmgbfl )
NCT00266409 (CTgov)	Phase 4	Anxiety \| Panic Disorder \| Generalized anxiety disorder	418	SSRI/SNRI+Niravam (Panic: Niravam+SSRI/SNRI)	aveudhsdga(sdgmyfxyrm) = gnhqqovutf fvjchbabnr (nunuaerasg, ihuyhldfqs - rhajlquphz) View more	-	02 Oct 2009
				SSRI/SNRI (Panic: SSRI/SNRI Alone)	aveudhsdga(sdgmyfxyrm) = jqybsnwnbj fvjchbabnr (nunuaerasg, kfaowdgoev - glkyrukgam) View more
NCT00830024 (CTgov)	Phase 1	-	36	Alprazolam Extended-Release 3 mg Tablets	mqshphbszw(gqxgnhbqmy) = enkggyfhjj yfsfpuuyrn (xaufunuacm, xybrqizbnv - uifjlxhxec) View more	-	21 Jul 2009

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis